Bisphosphonate-ciprofloxacin bound to Skelite™ is a prototype for enhancing experimental local antibiotic delivery to injured bone

T. B. Buxton, D. S. Walsh, S. B. Harvey, J. C. McPherson, J. F. Hartmann, Kent Plowman

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Background: The risk of osteomyelitis after open bone fracture may be reduced by locally applied antibiotics. ENC-41-HP (E41), which comprises ciprofloxacin linked to a 'bone seeking' bisphosphonate, loaded on to carrier Skelite calcium phosphate granules (E41-Skelite™) has favourable in vitro characteristics for application to wounded bone. This study assessed E41-Skelite™ in a rat model of acute tibial osteomyelitis. Methods: Mechanically induced tibial troughs were contaminated with approximately log10 4 colony forming units (c.f.u.) of Staphylococcus aureus (Cowan 1 strain) 'resistant' to E41 (minimum inhibitory concentration 8-16 μg/ml), lavaged and packed with Skelite alone, or with E41-Skelite™ slurry. Animals were killed at 24 h (n = 62), 72 h (n = 46) or 14 days (n = 12), and each tibia was assessed for S. aureus load (c.f.u./g tibia) and histological appearance (14 days only). Results: At 24 and 72 h, the tibias of rats treated with E41-Skelite™ (n = 54) had a significantly lower mean(s.e.m.) load of S. aureus than animals that received Skelite alone (n = 54): log10 3.6(0.2) versus 6.4(0.1) c.f.u./g respectively at 24 h (P < 0.001, Mann-Whitney rank sum test) and log10 4.4(0.2) versus 6.6(0.1) c.f.u./g at 72 h (P < 0.001). At 14 days, E41-Skelite™-treated tibias had fewer bacteria, no signs of osteomyelitis and histological signs of healing. Conclusions: E41-Skelite™, a prototype granulated topical antibiotic delivery system, reduced the development of infection in experimental bone wounds.

Original languageEnglish (US)
Pages (from-to)1192-1196
Number of pages5
JournalBritish Journal of Surgery
Volume91
Issue number9
DOIs
StatePublished - Sep 1 2004

Fingerprint

Diphosphonates
Ciprofloxacin
Tibia
Osteomyelitis
Stem Cells
Anti-Bacterial Agents
Staphylococcus aureus
Bone and Bones
Open Fractures
Bone Fractures
Microbial Sensitivity Tests
Nonparametric Statistics
Bacteria
Wounds and Injuries
Infection

ASJC Scopus subject areas

  • Surgery

Cite this

Bisphosphonate-ciprofloxacin bound to Skelite™ is a prototype for enhancing experimental local antibiotic delivery to injured bone. / Buxton, T. B.; Walsh, D. S.; Harvey, S. B.; McPherson, J. C.; Hartmann, J. F.; Plowman, Kent.

In: British Journal of Surgery, Vol. 91, No. 9, 01.09.2004, p. 1192-1196.

Research output: Contribution to journalArticle

Buxton, T. B. ; Walsh, D. S. ; Harvey, S. B. ; McPherson, J. C. ; Hartmann, J. F. ; Plowman, Kent. / Bisphosphonate-ciprofloxacin bound to Skelite™ is a prototype for enhancing experimental local antibiotic delivery to injured bone. In: British Journal of Surgery. 2004 ; Vol. 91, No. 9. pp. 1192-1196.
@article{bd3275fec7234448a1c8f9caba02802a,
title = "Bisphosphonate-ciprofloxacin bound to Skelite™ is a prototype for enhancing experimental local antibiotic delivery to injured bone",
abstract = "Background: The risk of osteomyelitis after open bone fracture may be reduced by locally applied antibiotics. ENC-41-HP (E41), which comprises ciprofloxacin linked to a 'bone seeking' bisphosphonate, loaded on to carrier Skelite calcium phosphate granules (E41-Skelite™) has favourable in vitro characteristics for application to wounded bone. This study assessed E41-Skelite™ in a rat model of acute tibial osteomyelitis. Methods: Mechanically induced tibial troughs were contaminated with approximately log10 4 colony forming units (c.f.u.) of Staphylococcus aureus (Cowan 1 strain) 'resistant' to E41 (minimum inhibitory concentration 8-16 μg/ml), lavaged and packed with Skelite alone, or with E41-Skelite™ slurry. Animals were killed at 24 h (n = 62), 72 h (n = 46) or 14 days (n = 12), and each tibia was assessed for S. aureus load (c.f.u./g tibia) and histological appearance (14 days only). Results: At 24 and 72 h, the tibias of rats treated with E41-Skelite™ (n = 54) had a significantly lower mean(s.e.m.) load of S. aureus than animals that received Skelite alone (n = 54): log10 3.6(0.2) versus 6.4(0.1) c.f.u./g respectively at 24 h (P < 0.001, Mann-Whitney rank sum test) and log10 4.4(0.2) versus 6.6(0.1) c.f.u./g at 72 h (P < 0.001). At 14 days, E41-Skelite™-treated tibias had fewer bacteria, no signs of osteomyelitis and histological signs of healing. Conclusions: E41-Skelite™, a prototype granulated topical antibiotic delivery system, reduced the development of infection in experimental bone wounds.",
author = "Buxton, {T. B.} and Walsh, {D. S.} and Harvey, {S. B.} and McPherson, {J. C.} and Hartmann, {J. F.} and Kent Plowman",
year = "2004",
month = "9",
day = "1",
doi = "10.1002/bjs.4644",
language = "English (US)",
volume = "91",
pages = "1192--1196",
journal = "British Journal of Surgery",
issn = "0007-1323",
publisher = "John Wiley and Sons Ltd",
number = "9",

}

TY - JOUR

T1 - Bisphosphonate-ciprofloxacin bound to Skelite™ is a prototype for enhancing experimental local antibiotic delivery to injured bone

AU - Buxton, T. B.

AU - Walsh, D. S.

AU - Harvey, S. B.

AU - McPherson, J. C.

AU - Hartmann, J. F.

AU - Plowman, Kent

PY - 2004/9/1

Y1 - 2004/9/1

N2 - Background: The risk of osteomyelitis after open bone fracture may be reduced by locally applied antibiotics. ENC-41-HP (E41), which comprises ciprofloxacin linked to a 'bone seeking' bisphosphonate, loaded on to carrier Skelite calcium phosphate granules (E41-Skelite™) has favourable in vitro characteristics for application to wounded bone. This study assessed E41-Skelite™ in a rat model of acute tibial osteomyelitis. Methods: Mechanically induced tibial troughs were contaminated with approximately log10 4 colony forming units (c.f.u.) of Staphylococcus aureus (Cowan 1 strain) 'resistant' to E41 (minimum inhibitory concentration 8-16 μg/ml), lavaged and packed with Skelite alone, or with E41-Skelite™ slurry. Animals were killed at 24 h (n = 62), 72 h (n = 46) or 14 days (n = 12), and each tibia was assessed for S. aureus load (c.f.u./g tibia) and histological appearance (14 days only). Results: At 24 and 72 h, the tibias of rats treated with E41-Skelite™ (n = 54) had a significantly lower mean(s.e.m.) load of S. aureus than animals that received Skelite alone (n = 54): log10 3.6(0.2) versus 6.4(0.1) c.f.u./g respectively at 24 h (P < 0.001, Mann-Whitney rank sum test) and log10 4.4(0.2) versus 6.6(0.1) c.f.u./g at 72 h (P < 0.001). At 14 days, E41-Skelite™-treated tibias had fewer bacteria, no signs of osteomyelitis and histological signs of healing. Conclusions: E41-Skelite™, a prototype granulated topical antibiotic delivery system, reduced the development of infection in experimental bone wounds.

AB - Background: The risk of osteomyelitis after open bone fracture may be reduced by locally applied antibiotics. ENC-41-HP (E41), which comprises ciprofloxacin linked to a 'bone seeking' bisphosphonate, loaded on to carrier Skelite calcium phosphate granules (E41-Skelite™) has favourable in vitro characteristics for application to wounded bone. This study assessed E41-Skelite™ in a rat model of acute tibial osteomyelitis. Methods: Mechanically induced tibial troughs were contaminated with approximately log10 4 colony forming units (c.f.u.) of Staphylococcus aureus (Cowan 1 strain) 'resistant' to E41 (minimum inhibitory concentration 8-16 μg/ml), lavaged and packed with Skelite alone, or with E41-Skelite™ slurry. Animals were killed at 24 h (n = 62), 72 h (n = 46) or 14 days (n = 12), and each tibia was assessed for S. aureus load (c.f.u./g tibia) and histological appearance (14 days only). Results: At 24 and 72 h, the tibias of rats treated with E41-Skelite™ (n = 54) had a significantly lower mean(s.e.m.) load of S. aureus than animals that received Skelite alone (n = 54): log10 3.6(0.2) versus 6.4(0.1) c.f.u./g respectively at 24 h (P < 0.001, Mann-Whitney rank sum test) and log10 4.4(0.2) versus 6.6(0.1) c.f.u./g at 72 h (P < 0.001). At 14 days, E41-Skelite™-treated tibias had fewer bacteria, no signs of osteomyelitis and histological signs of healing. Conclusions: E41-Skelite™, a prototype granulated topical antibiotic delivery system, reduced the development of infection in experimental bone wounds.

UR - http://www.scopus.com/inward/record.url?scp=4444313709&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4444313709&partnerID=8YFLogxK

U2 - 10.1002/bjs.4644

DO - 10.1002/bjs.4644

M3 - Article

C2 - 15449273

AN - SCOPUS:4444313709

VL - 91

SP - 1192

EP - 1196

JO - British Journal of Surgery

JF - British Journal of Surgery

SN - 0007-1323

IS - 9

ER -